Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Frog molecule could provide drug treatment for brain tumours

27.06.2007
A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.

Known as Amphinase, the molecule recognises the sugary coating found on a tumour cell and binds to its surface before invading the cell and inactivating the RNA it contains, causing the tumour to die.

In new research published in the Journal of Molecular Biology, scientists from the University of Bath (UK) and Alfacell Corporation (USA) describe the first complete analysis of the structural and chemical properties of the molecule.

Although it could potentially be used as a treatment for many forms of cancer, Amphinase offers greatest hope in the treatment of brain tumours, for which complex surgery and chemotherapy are the only current treatments.

... more about:
»Amphinase »ribonuclease »trials »tumour

“This is a very exciting molecule,” said Professor Ravi Acharya, from the Department of Biology & Biochemistry at the University of Bath.

“It is rather like Mother Nature’s very own magic bullet for recognising and destroying cancer cells.

“It is highly specific at hunting and destroying tumour cells, is easily synthesised in the laboratory and offers great hope as a therapeutic treatment of the future.”

Amphinase is a version of a ribonuclease enzyme that has been isolated from the oocytes (egg cells) of the Northern Leopard frog.

Ribonucleases are a common type of enzyme found in all organisms. They are responsible for tidying up free-floating strands of RNA cells by latching on to the molecule and cutting it into smaller sections.

In areas of the cell where the RNA is needed for essential functions, ribonucleases are prevented from working by inhibitor molecules. But because Amphinase is an amphibian ribonuclease, it can evade the mammalian inhibitor molecules to attack the cancer cells.

As a treatment, it is most likely to be injected into the area where it is needed. It will have no effect on other cells because it is only capable of recognising and binding to the sugar coating of tumour cells.

“Amphinase is in the very early stages of development, so it is likely to be several years and many trials before it could be developed into a treatment for patients,” said Professor Acharya and his colleagues Drs Umesh Singh and Daniel Holloway.

“Having said that, the early data is promising and through this study we have provided the kind of information needed if approval for use is requested in the future.”

Amphinase is the second anti-tumour ribonuclease to be isolated by Alfacell Corporation from Rana pipiens oocytes.

The other, ONCONASE(R) (ranpirnase), is currently in late-stage clinical trials as a treatment for unresectable malignant mesothelioma, a rare and fatal form of lung cancer, and in Phase I/II clinical trials in non-small cell lung cancer and other solid tumours.

“We are pleased with the superb work performed by Professor Acharya and his talented team at the University of Bath,” commented Kuslima Shogen, Alfacell’s chairman and chief executive officer.

“Their work is critical to the continued development and understanding of our family of novel ribonuclease based therapeutics with the potential to help patients suffering from cancer and other dismal diseases.”

The company is now working on pre-clinical trials of Amphinase with a view to beginning clinical trials in the future.

Andrew McLaughlin | alfa
Further information:
http://www.bath.ac.uk/news/2007/6/26/amphinase.html

Further reports about: Amphinase ribonuclease trials tumour

More articles from Life Sciences:

nachricht Protein interaction helps Yersinia cause disease
21.08.2018 | Schwedischer Forschungsrat - The Swedish Research Council

nachricht Nanobot pumps destroy nerve agents
21.08.2018 | American Chemical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

A paper battery powered by bacteria

21.08.2018 | Power and Electrical Engineering

Protein interaction helps Yersinia cause disease

21.08.2018 | Life Sciences

Biosensor allows real-time oxygen monitoring for 'organs-on-a-chip'

21.08.2018 | Medical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>